Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial.

Celgosivir (6-O-butanoyl castanospermine), a pro-drug of the naturally occurring castanospermine, is an inhibitor of α-glucosidase I and II that is found to be a potent inhibitor of several enveloped viruses including all four serotypes of dengue virus. We showed previously that the compound fully protected AG129 mice from lethal infection with a mouse adapted dengue virus at a dose of 50mg/kg twice daily (BID) for 5days and was effective even after 48h delayed treatment. Here we show that the protection by celgosivir is dose- and schedule-dependent and that a twice-a-day regimen of 50, 25 or 10mg/kg is more protective than a single daily dose of 100mg/kg. Treatment with 50mg/kg BID castanospermine had comparable efficacy as 25mg/kg BID celgosivir, suggesting that celgosivir is approximately twice as potent as castanospermine with respect to in vivo antiviral efficacy. Pharmacokinetics (PK) studies of celgosivir in mice showed that it rapidly metabolized to castanospermine. Simulation of the PK data with the survival data for the various doses of celgosivir tested suggests that the steady-state minimum concentration is a critical parameter to note in choosing dose and schedule. These results influenced the selection of the dose regimen for a proof-of-concept clinical trial of celgosivir as a treatment against dengue fever.
AuthorsSatoru Watanabe, Abhay P S Rathore, Cynthia Sung, Fan Lu, Yok Moi Khoo, John Connolly, Jenny Low, Eng Eong Ooi, How Sung Lee, Subhash G Vasudevan
JournalAntiviral research (Antiviral Res) Vol. 96 Issue 1 Pg. 32-5 (Oct 2012) ISSN: 1872-9096 [Electronic] Netherlands
PMID22867971 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier B.V. All rights reserved.
Chemical References
  • Antiviral Agents
  • Indolizines
  • celgosivir
  • castanospermine
  • Animals
  • Antiviral Agents (administration & dosage, pharmacokinetics)
  • Dengue (drug therapy)
  • Dengue Virus (drug effects)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Therapy (methods)
  • Indolizines (administration & dosage, pharmacokinetics)
  • Mice
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: